Showing posts with label Pharmaceuticals And Healthcare Market. Show all posts
Showing posts with label Pharmaceuticals And Healthcare Market. Show all posts

Monday 1 December 2014

MRRBIZ News: Frontier Pharma - NSCLC - Identifying And Commercializing First-In-Class Innovation In Non-Small-Cell Lung Carcinoma

The Report Frontier Pharma - NSCLC - Identifying and Commercializing First-in-Class Innovation in Non-Small-Cell Lung Carcinoma provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz


According to the report, growth in the Non-Small Cell Lung Cancer market will be mainly driven by innovative therapies entering the squamous cell carcinoma market segment. Unlike the non-squamous market segment that currently lacks effective treatment, growth in the NSCLC segment will grow at a moderate Compound Annual Growth Rate (CAGR) of approximately 6.6% till 2020. The value of the Non-Small Cell Lung Cancer (NSCLC) market is expected to grow significantly from US$5.1 billion in 2013 to reach a value of US$7.9 billion in 2020 over the forecast period. This growth will be marked across eight developed nations in the world.

To Read Complete Report with Toc: http://www.marketresearchreports.biz/analysis/228987

The Frontier Pharma - NSCLC - Identifying and Commercializing First-in-Class Innovation in Non-Small-Cell Lung Carcinoma report analyzes innovation in NSCLC segment in the context of the current market landscape and overall pipeline activities. It also includes a comprehensive review of the pipeline for first-in-class therapies, deals surrounding the first-in-class products and analyzes molecule types and molecular target by stage of development. The report also focuses and studies the three main NSCLC subtypes such as squamous cell, adenocarcinoma, and large cell carcinoma.

Studies show that currently the NSCLC pipeline has 389 products that are in an active development stage across various other stages in the global market. However, the Non-Small Cell Lung Cancer (NSCLC) market accrues diversity due to the presence of 122 first-in-class products that accounts for around 38% of the overall pipeline therapies in the market. This poses a stark difference between the range of therapies available in the pipeline and those that the market already comprises of.

The global Frontier Pharma - NSCLC - Identifying and Commercializing First-in-Class Innovation in Non-Small-Cell Lung Carcinoma market finding has strategic implications based on a broad range of market participants. This is due to the market and development landscape that effectively favors first-in-class over non-first-in-class innovation and development in several ways, chiefly through greater revenue and faster approval for both small and large market players.

Nevertheless, despite the high attrition rate in the NSCLC segment, various first-in-class therapies that enter into the market have the potential to improve and transform the NSCLC treatment landscape.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/228987

From the perspective of First-in-Class Products in Licensing and Co-development Deals, the report discusses a total of 117 first-in-class products that are in the pipeline but have not been entered into the co-development or licensing deal. Although there is low sample size in the market, deals in the first-in-class NSCLC products occur earlier in development as compared to the non-first-in-class counterparts. The NSCLC products also offer a lucrative investment prospect on average and higher deal values. 

The report analysis shows significant variations in the NSCLC first-in-class targets in alignment to frequent gene mutations. It also identifies the in-depth analysis of the most promising first-in-class targets that are based on different scientific and clinical parameters.


Related Reports:

Frontier Pharma: Breast Cancer - Identifying And Commercializing First-In-Class Innovation: http://www.marketresearchreports.biz/analysis/223632

The Report Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz

Exceptionally Large and Innovative Pipeline

The breast cancer pipeline is the largest in the pharmaceutical industry with 815 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations in this pipeline is exceptional; GBI Research analysis identified 253 first-in-class programs in the breast cancer pipeline, acting on 176 first-in-class molecular targets. This accounts for some 39% of all products with a disclosed molecular target and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as, despite the high attrition rate in breast cancer, it is highly likely many of the first-in-class technologies will reach the market over the coming decade and may transform the clinical and commercial landscape.

Alignment of First-in-Class Molecular Target with Disease Causation
Click Here To Download Detail Reporthttp://www.marketresearchreports.biz/sample/sample/223632

One of the key trends in oncology and in breast cancer in particular over the last decade is the clinical and commercial impact of targeted therapies designed to target proteins in signaling pathways that are frequently mutated in a significant proportion of the patient population. By aligning the molecular targets for therapeutic intervention with disease causation and/or propagation, these therapies limit the systemic cytotoxic effects whilst inhibiting tumor-promoting signaling pathways. Such strategies thereby typically achieve superior efficacy and safety profiles.


Frontier Pharma: Psoriasis - Identifying And Commercializing First-In-Class Innovation: http://www.marketresearchreports.biz/analysis/206412

The Report Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz

Psoriasis is a chronic, inflammatory disease triggered by deregulated Thymus-derived (T) cells, resulting inflammation and benign hyperplasia of keratinocytes within the skin. Manifestations of affected skin are red, thickened plaques with an overlying silver-white scale, which significantly impairs the patient’s physical and mental wellbeing. The primary cause of psoriasis is unknown, as are the mechanisms that lead to immune cells directing inflammatory responses towards the skin. Within the lucrative autoimmune market, the psoriasis market has grown considerably due to the repositioning of all three marketed Tumor Necrosis Factor (TNF) inhibitors: Humira (adalimumab) and Enbrel (etanercept) which were originally approved for rheumatoid arthritis, and also Remicade (infliximab), the first biologic to be approved for Crohn’s disease, an autoimmune disease which largely affects the gastrointestinal system.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/206412

Table of Contents

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 The Case for Innovation
2.1 Growing Opportunities for Biologic Products
2.2 Diversification of Molecular Targets
2.3 Innovative First-in-Class Product Developments Remain Attractive
2.4 Changes in the Clinical and Commercial Environment Will be More Favorable to Products That Target Niche Indications and Patient Populations
2.5 Innovation in Psoriasis

For More latest Reports Under Pharmaceutical Market Research Reports Category: http://www.marketresearchreports.biz/category/38

The global pharmaceutical market is almost a trillion dollar industry. The pharmaceutical market has been playing a very important role in the area of scientific advancement and has contributed significantly to economic growth all across the globe. The global pharmaceutical market consists of a wide range of mid-sized, and big companies, and multinational corporations like biopharmaceutical firms, pharmaceutical companies, virtual pharmas, generic manufacturer
biotechnology firms. The pharmaceutical market also includes various service and ancillary support firms which provide raw materials, undertake contract research projects, contract sales, manufacturing technologies, and regulatory guidance.

The global pharmaceutical market is witnessing satisfactory growth owing to factors like high incidence of chronic and contagious diseases, and rising life expectancy. Research and development related investments are also taking place in the pharmaceutical market due to rising demand for innovative and better drugs. An emerging segment in the pharmaceutical market is that of biopharmaceuticals which is extensively applied in proteomics, drug discovery, and genomics.

Monday 14 April 2014

HIV-1 Infection - Pipeline Review, H1 Market Trends, Estimates And Forecasts 2014: Industrial Report

MarketResearchReports.Biz presents this most up-to-date research on "Research Report On HIV-1 Infection - Pipeline Review, H1 Market" 2014

HIV-1 Infection - Pipeline Review, H1 2014, provides an overview of the HIV-1 Infections therapeutic pipeline.


This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects.

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis-details/hiv-1-infection-pipeline-review-h1-2014

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

To Get Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/195027

Scope

- The report provides a snapshot of the global therapeutic landscape of HIV-1 Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for HIV-1 Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the HIV-1 Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

To Read Complete Report with TOC: http://www.marketresearchreports.biz/sample/sample/195027

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


About us

MarketResearchReports.biz
is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. 

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

Website: http://www.marketresearchreports.biz/
Blog: http://mrrfocuseconomics.blogspot.com/

Friday 11 April 2014

Pipeline Review Of Hospital Acquired Pneumonia Drugs Market Status, Opportunities, Market Forecasts 2013 - 2019: Popular Market Report

Pipeline Review Of Hospital Acquired Pneumonia Drugs - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

Hospital acquired pneumonia (HAP) is a pulmonary infectionthat occurs after 48 hours of hospitalization and it was not present at the time of admission. It is the most-common infection and is usually bacterial in origin. The symptoms of pneumonia are cough, fever, nausea, vomiting, shortness of breath, loss of appetite, decreased blood pressure and high heart rate.HAP is the major cause of high morbidity, mortality and cost.Intubation and mechanical ventilation (MV) are risk factors for developingHAP. The development of new diagnostic tools and therapeutic weapons is urgently needed to face the epidemic of multidrug-resistant pathogens.

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis-details/pipeline-review-of-hospital-acquired-pneumonia-drugs-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019

Hospital Acquired Pneumonia (HAP) - Pipeline Review, provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), with latest updates. Some of the players involved in the therapeutic development for HAP are AstraZeneca, Cubist Pharmaceuticals, Basilea Pharmaceutica, Melinta Therapeutics, Biota Pharmaceuticals, Aridis Pharmaceuticals, Meiji Seika Pharma, Adenium Biotech and Tetraphase Pharmaceuticals.

Scope

•    The report provides a snapshot of the global Hospital Acquired Pneumonia Drugs Market.
•    The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
•    The report reviews key players involved in the development of Hospital Acquired Pneumonia Drugs and enlists all their major and minor projects
•    The report summarizes all the dormant and discontinued pipeline projects
•    Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
•    Coverage of the Hospital Acquired Pneumonia Drugs pipeline on the basis of target, MoA, route of administration and molecule type
•    Latest news and deals relating related to pipeline products

To Get Download Full Report with TOC: http://www.marketresearchreports.biz/sample/toc/194543

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include


•    North America
•    Asia Pacific
•    Europe
•    Rest of the World 

This report provides comprehensive analysis of

•    Market growth drivers
•    Factors limiting market growth
•    Current market trends
•    Market structure
•    Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

To Read Complete Report with TOC: http://www.marketresearchreports.biz/analysis/194543

Reasons to buy

•    Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
•    Develop strategic initiatives by understanding the focus areas of leading companies
•    Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
•    Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


About us

MarketResearchReports.biz
is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. 

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

Website: http://www.marketresearchreports.biz/
Blog: http://mrrfocuseconomics.blogspot.com/

Thursday 10 April 2014

Arromax Pharmatech, Co. Ltd. - Product Pipeline Review Market News 2014: Worldwide Business Survey

Market survey On Arromax Pharmatech, Co. Ltd. - Product Pipeline Review - 2014: Global Industry Analysis, Size, Share, Growth, Trends and Forecast

Global Markets Direct’s, ‘Arromax Pharmatech, Co. Ltd. - Product Pipeline Review - 2014’, provides an overview of the Arromax Pharmatech, Co. Ltd.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Arromax Pharmatech, Co. Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis-details/arromax-pharmatech-co-ltd-product-pipeline-review-2014

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To Get Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/193831

Scope

•    The report provides brief overview of Arromax Pharmatech, Co. Ltd. including business description, key information and facts, and its locations and subsidiaries
•    The report reviews current pipeline of Arromax Pharmatech, Co. Ltd.’s human therapeutic division and enlists all their major and minor projects
•    The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
•    Special feature on out-licensed and partnered product portfolio
•    The report summarizes all the dormant and discontinued pipeline projects
•    Latest company statement
•    Latest news and deals relating to the Arromax Pharmatech, Co. Ltd.’s pipeline products

To Read Complete Report with TOC: http://www.marketresearchreports.biz/analysis/193831

Reasons to buy


•    Evaluate Arromax Pharmatech, Co. Ltd.’s strategic position with total access to detailed information on its product pipeline
•    Assess the growth potential of Arromax Pharmatech, Co. Ltd. in its therapy areas of focus
•    Identify new drug targets and therapeutic classes in the Arromax Pharmatech, Co. Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
•    Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
•    Develop strategic initiatives by understanding the focus areas of Arromax Pharmatech, Co. Ltd. and exploit collaboration and partnership opportunities
•    Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
•    Plan mergers and acquisitions effectively by identifying the most promising pipeline of Arromax Pharmatech, Co. Ltd.
•    Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
•    Explore the dormant and discontinued projects of Arromax Pharmatech, Co. Ltd. and identify potential opportunities in those areas
•    Avoid Intellectual Property Rights related issues


About us

MarketResearchReports.biz
is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. 

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

Website: http://www.marketresearchreports.biz/
Blog: http://mrrfocuseconomics.blogspot.com/

Psoriasis - Pipeline Review, H1 Market Trends & Growth Research Report 2014: Report Overview

Market Survey On Psoriasis - Pipeline Review, H1 2014: Global Industry Emerging Opportunities, Trends, Size, Drivers, Strategies, Products And Competitive Landscape

‘Psoriasis - Pipeline Review, H1 2014’, provides an overview of the Psoriasis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects.

Browse Full Report with TOC: http://www.marketresearchreports.biz/analysis-details/psoriasis-pipeline-review-h1-2014

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/193853

Scope

•    The report provides a snapshot of the global therapeutic landscape of Psoriasis
•    The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
•    The report reviews key players involved in the therapeutics development for Psoriasis and enlists all their major and minor projects
•    The report summarizes all the dormant and discontinued pipeline projects
•    A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
•    Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
•    A detailed assessment of monotherapy and combination therapy pipeline projects
•    Coverage of the Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
•    Latest news and deals relating related to pipeline products
Reasons to buy
•    Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
•    Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
•    Develop strategic initiatives by understanding the focus areas of leading companies
•    Identify and understand important and diverse types of therapeutics under development for Psoriasis
•    Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Visit Analysis Report: http://www.marketresearchreports.biz/analysis/193853

Table of Contents

Introduction


Psoriasis Overview
Therapeutics Development
Psoriasis - Therapeutics under Development by Companies
Psoriasis - Therapeutics under Investigation by Universities/Institutes
Psoriasis - Pipeline Products Glance
Psoriasis - Products under Development by Companies
Psoriasis - Products under Investigation by Universities/Institutes
Psoriasis - Companies Involved in Therapeutics Development
Psoriasis - Therapeutics Assessment
Drug Profiles
Psoriasis - Recent Pipeline Updates
Psoriasis - Dormant Projects
Psoriasis - Discontinued Products
Psoriasis - Product Development Milestones

Appendix

Number of Products under Development for Psoriasis, H1 2014
Number of Products under Development for Psoriasis - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Development by Companies, H1 2014 (Contd..2)
Number of Products under Development by Companies, H1 2014 (Contd..3)
Number of Products under Development by Companies, H1 2014 (Contd..4)
Number of Products under Development by Companies, H1 2014 (Contd..5)
Number of Products under Development by Companies, H1 2014 (Contd..6)
Number of Products under Development by Companies, H1 2014 (Contd..7)

Psoriasis - Pipeline by Cold Genesys, Inc., H1 2014
Psoriasis - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H1 2014
Psoriasis - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2014
Psoriasis - Pipeline by PsiOxus Therapeutics, Ltd., H1 2014
Psoriasis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014
Psoriasis - Pipeline by CureFAKtor Pharmaceuticals. LLC, H1 2014
Psoriasis - Pipeline by Kancera AB, H1 2014
Psoriasis - Pipeline by Jasco Pharmaceuticals, LLC., H1 2014


About us

MarketResearchReports.biz
is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. 

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

Website: http://www.marketresearchreports.biz/
Blog: http://market-recent-report.blogspot.com/